Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
OBJECTIVE
GH replacement is widely used in the management of patients with adult-onset (AO)-GH deficiency (GHD). In most cases, AO-GHD arises as a result of pituitary/peripituitary tumours and/or their treatment, but the effect of GH replacement on recurrence/regrowth of these tumours is unknown. The aim of this study was to examine the effect of GH replacement in a group of patients with primary tumours of the parasellar region, many of which (e.g. craniopharyngioma, glioma or germ cell tumours) might be anticipated to have a higher recurrence rate than secretory and nonsecretory anterior pituitary tumours.


METHODS
We report here our experience of prospective imaging in 50 consecutive patients (21 males; mean age 45.9 years) with nonanterior pituitary parasellar tumours treated with GH. All had severe GHD (peak serum GH 9 mU/l or less on dynamic testing) and were treated with an identical dose-titration regimen to maintain serum IGF-I concentrations between the median and upper end of the age-adjusted normal range. The primary diagnoses were: craniopharyngioma (28), germ cell tumour (8), arachnoid cyst (4), meningioma (4), glioma (4) and mensenchymal tumour (2). External pituitary irradiation had been given to 37 (74%) of patients. Measurements Surveillance imaging (magnetic resonance imaging (MRI) 70%, computed tomography (CT) 16%, both 14%) was performed at baseline (prior to GH), at 6--12 months, and then again yearly or as clinically indicated. Median follow-up was 36 months (range 7--129 months). All images were reviewed by the same radiologist.


RESULTS
Four patients had an apparent increase in tumour volume but in only one patient was it considered necessary to abandon GH replacement. In two of the four cases marginal increases in cystic parasellar tumours were not progressive; and in the fourth case apparent recurrence of a suprasellar germ cell tumour was shown to be acellular fibrous tissue only on biopsy. In all other cases either the appearances were unchanged or the amount of tissue was reduced during long-term follow-up on GH.


CONCLUSIONS
Overall, GH appears safe with respect to tumour recurrence over this time period in this patient group. Comparison with similar prospective series in patients not receiving GH replacement is desirable.
Chung
T T
TT
Department of Endocrinology, St Bartholomew's Hospital, London, UK.
Drake
W M
WM
Evanson
J
J
Walker
D
D
Plowman
P N
PN
Chew
S L
SL
Grossman
A B
AB
Besser
G M
GM
Monson
J P
JP
D000328:Adult; D001921:Brain / Q000473:pathology*; D001932:Brain Neoplasms / Q000150:complications / Q000628:therapy; D003131:Combined Modality Therapy; D003397:Craniopharyngioma / Q000150:complications / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D018237:Germinoma / Q000150:complications / Q000628:therapy; D005910:Glioma / Q000150:complications / Q000628:therapy; D013006:Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D020249:Hormone Replacement Therapy; D006801:Humans; D007018:Hypopituitarism / Q000188:drug therapy* / Q000209:etiology; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D010910:Pituitary Irradiation
D013006:Growth Hormone